Rolipram suppresses experimental autoimmune neuritis and prevents relapses in Lewis rats

Neuropharmacology

Volumn 39, Issue 2, 2000, Pages 324-333

  Zou, Li Ping ^a   Deretzi, Georgia ^a   Pelidou, Sigliti Henrietta ^a   Levi, Michael ^b   Wahren, Britta ^b   Quiding, Cecilia ^a   Van Der Meide, Peter ^c   Zhu, Jie ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Experimental autoimmune neuritis; Guillain Barre syndrome; Rolipram; TNF

Indexed keywords

GAMMA INTERFERON; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; GUILLAIN BARRE SYNDROME; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MALE; NEURITIS; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION;

ANIMALS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MALE; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; PEPTIDES; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, INBRED LEW; RECURRENCE; ROLIPRAM; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033987308     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00144-6     Document Type: Article

References (27)

1. Bakhiet M., Diab M., Zhu J., Lindqvist L., Link H. Potential role of autoantibodies in the regulation of cytokine responses during bacterial infections. Infection and Immunity. 65:1997;3300-3303.
2. Buttini M., Mir A., Appel K., Wiederhold K.H., Limota S., Gebicke-Haerter P.J., Boddeke H.W. Lipopolysaccharide induces expression of tumor necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram. British Journal of Pharmacology. 122:1997;1483-1489.
3. Chensue S.W., Remick D.G., Shmyr-Forsch C., Beals T.F., Kunkel S.L. Immunohistochemical demonstration of cytoplasmic and membrane-associated tumor necrosis factor in murine macrophages. American Journal of Pathology. 133:1988;564-572.
4. Essayan D.M., Huang S.K., Kagey-Sobotka A., Lichtenstein L.M. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. Journal of Allergy and Clinical Immunology. 99:1997;28-37.
5. Exley A.R., Smith N., Winer J.B. Tumour necrosis factor-α and other cytokines in Guillain-Barré syndrome. Journal of Neurology, Neurosurgery and Psychiatry. 57:1994;1118-1120.
6. Ishii O., Yamada H., Ohya S., Moriuchi E., Kase C., Ichikawa Y., Yamasaki K. Remission induction after pentoxifylline treatment in a patient with rheumatoid arthritis. Ryumachi. 37:1997;810-815.
7. Jung S., Zielasek J., Köllner G., Donhauser T., Toyka K., Hartung H.P. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. Journal of Neuroimmunology. 68:1996;1-11.
8. Kadlubowski M., Hughes R.A.C. Identification of the neuritogen for experimental allergic neuritis. Nature. 277:1979;140-141.
9. King R.H., Craggs R.I., Gross M.L., Thomas P.K. Effects of glucocorticoids on experimental allergic neuritis. Experimental Neurology. 87:1985;9-19.
10. Kumari M., Cover P.O., Poyser R.H., Buckingham J.C. Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by three selective type-4 phosphodiesterase inhibitors: in vitro and in vivo studies. British Journal of Pharmacology. 121:1997;459-468.
11. Marriott J.B., Westby M., Cookson S., Guckian M., Goodbourn S., Muller G., Shire M.G., Stirling D., Dalgleish A.G. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. Journal of Immunology. 161:1998;4236-4243.
12. Milner P.A., Lovelidge C.A., Taylor W.A., Hughes R.A.C. P0 myelin protein produces experimental allergic neuritis in Lewis rats. Journal of Neurological Science. 79:1987;275-285.
13. Norton W.T., Poduslo S.E. Myelination in rat brain: Method of myelin isolation. Journal of Neurochemistry. 21:1973;749-757.
14. Nyman U., Mussener Å., Larsson E., Lorentzen J., Klareskog L. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram. Clinical and Experimental Immunology. 108:1997;415-419.
15. Olee T., Powers J.M., Brostoff S.W. A T cell epitope for experimental allergic neuritis. Journal of Neuroimmunology. 19:1988;167-173.
16. Ohnishi A., Yamamoto T., Her Q., Han M., Murai Y., Ikeda M. The effect of brain-derived neurotrophic factor on regeneration of nerve fibers after crush injury - morphometric evaluation. Sangyo Ika. Daigaku. Zasshi. 18:1996;267-271.
17. Olsson T., Wang W-Z., Höjeberg B., Kostulas V., Jiang Y.P., Andersson G., Ekre H.P., Link H. Autoreactive T lymphocytes in multiple sclerosis determined by antigen induced secretion of interferon-gamma. Journal of Clinical Investigation. 86:1990;981-985.
18. Pettipher E.R., Labasi J.M., Salter E.D., Stam E.J., Cheng J.B., Griffiths R.J. Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram. British Journal of Pharmacology. 117:1996;1530-1534.
19. Pettipher E.R., Eskra J.D., Labasi J.M. The inhibitory effect of rolipram on TNF-alpha production in mouse blood ex vivo is dependent upon the release of corticosterone and adrenaline. Cytokine. 9:1997;582-586.
20. Rostami A., Gregorian S.K., Brown M.J., Pleasure D.E. Induction of severe experimental autoimmune neuritis with a synthetic peptide corresponding to the 53-78 amino acid sequence of the myelin P2 protein. Journal of Neuroimmunology. 30:1990;145-151.
21. Ross S.E., Williams R.O., Mason L.J., Mauri C., Marinova-Mutafchieva L., Malfait A.M., Maini R.N., Feldmann M. Suppression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. Journal of Immunology. 159:1997;6253-6259.
22. Said G., Hontebeyrie-Joskowiecz M. Nerve lesions induced by macrophage activation. Research in Immunology. 143:1992;589-599.
23. Sommer N., Martin R., McFarland H.F., Quigley L., Cannella B., Raine C.S., Scott D.E., Raine C.S., Scott D.E., Loschmann P.A., Racke M.K. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. Journal of Neuroimmunology. 79:1997;54-61.
24. Sommer N., Löschmann P.A., Northoff G.H., Weller M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmuller A., Fontana A., Dichgans J., Martin R. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Medicine. 1:1995;244-248.
25. Souness J.E., Griffin M., Maslen C., Ebsworth K., Scott L.C., Pollock K., Palfreyman M.N., Karlsson J.A. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'lo-affinity' phosphodiesterase 4 conformer. British Journal of Pharmacology. 118:1996;649-658.
26. Waksman B.H., Adams R.D. Allergic neuritis: an experimental disease of rabbit induced by the injection of peripheral nervous tissue and adjuvant. Journal of Experimental Medicine. 102:1955;213-225.
27. Zhu J., Bai X.F., Mix E., Höjeberg B., Link H. Cytokines dichotomy in the peripheral nervous tissues influence the outcome of experimental allergic neuritis: Dynamic of mRNA expression for IL-1β, IL-6, Il-10, IL-12, TNF-α and TNF-β as well as cytolysin. Clinical Immunology and Immunopathology. 84:1997;85-94.